Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Combination therapies for personalized cancer medicine (COMBATCANCER)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2019,

All cancers arise due to alterations in their genomes. Although insight into the genetic lesions in tumours by genome sequencing does already assist in selecting some drug regimens, it rarely results in disease eradication due to the emergence of drug-resistant clones. More sophisticated combination therapies in which several oncogenic pathways are targeted simultaneously or in a particular seque ...
Voir le projet

 2

 TERMINÉ 

Mechanistic insights into the impact of tumor-associated neutrophils on metastatic breast cancer (InflaMet)

Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,

Metastatic disease is still largely unexplored, poorly understood and incurable. Accumulating evidence indicates that cells and mediators of the immune system can facilitate metastasis. Neutrophil accumulation in cancer patients has been associated with metastasis formation. In mouse tumor models, neutrophils have been reported to be pro- or anti- metastatic, but the underlying mechanisms involved ...
Voir le projet

 1

 TERMINÉ 

Advanced T-cell Engineered for Cancer Therapy (ATECT)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,

"T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to ...
Voir le projet

 6

 TERMINÉ 

Exploring enhancers’ Achilles Heel (enhReg)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Enhancers are genomic domains that regulate transcription of distantly located genes and that are characterized by specific chromatin signatures of histone methylation and acetylation patterns. Interestingly, RNA polymerase II (RNAPII) binds to a subset of enhancers and produces transcripts, called enhancer RNAs (eRNAs). These are produced bi-directionally and, in contrast to mRNAs and many other ...
Voir le projet

 1

 TERMINÉ 

Identification and functional validation of drugable targets/pathways for triple negative breast cancer (Triple-BC)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2018,

Patients suffering from triple-negative breast cancer (TNBC) have a poor prognosis as these tumors frequently confer resistance against chemotherapeutic agents and lack drug targets such as estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2. Insufficient knowledge on the biology of this specific breast tumor type and its heterogeneity hinder the identification of pot ...
Voir le projet

 3

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

Identification of Host Determinants for Virus Entry using a Haploid Genetic Approach (Viral Host Factors)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The most powerful and direct way to get insight into complex biological systems is to remove individual components and observe the consequences. Cultured human cells are widely used to model and study aspects of human disease. Although human cells can be analyzed and manipulated in numerous ways, their genome has remained refractory to efficient mutagenesis-based analysis.We have developed an inse ...
Voir le projet

 1

 TERMINÉ 

The European non-coding RNA network (RNATRAIN)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Voir le projet

 11

 TERMINÉ 

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE (ARTFORCE)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2017,

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:1. Optimizing local control by introducing novel radiation techniques resulting ...
Voir le projet

 14

 TERMINÉ 

The impact of chromosomal instability on health: Molecular causes and consequences of aneuploidy (PLOIDYNET)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Aneuploidy, an abnormal number of chromosomes, is a hallmark of cancer cells, affecting the majority of all human tumours. Aneuploidy arises when errors occur during mitosis, as the duplicated chromosomes are distributed between the two new daughter cells. Paradoxically, aneuploidy appears to have detrimental consequences for the physiology of untransformed cells in vitro, inhibiting rather than s ...
Voir le projet

 14

 TERMINÉ 

Genome-wide identification of factors controlling the telomere damage response and telomere-driven genomic instability (Telomeres)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Telomeres are specialized nucleoprotein complexes that protect chromosome ends against recognition as DNA breaks. In somatic cells telomeres shorten every cell division, eventually compromising telomere function. This leads to activation of a DNA damage response that induces irreversible growth arrest or cell death and serves to suppress tumorigenesis by preventing outgrowth of incipient cancer ce ...
Voir le projet

 1

 TERMINÉ 

Principles of Chromatin Organization (CHROMATINPRINCIPLES)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

"Chromatin is the ensemble of genomic DNA and hundreds of structural and regulatory proteins. Together these proteins govern the gene expression program of a cell. While biochemical and genetic approaches have tought us much about interactions between individual chromatin proteins, we still lack a “big picture” of chromatin: how is the entire interaction network of chromatin proteins organized?My ...
Voir le projet

 1

 TERMINÉ 

Epidemiological study to quantify risks for paediatric computerized tomography and to optimise doses (EPI-CT)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2017,

Diagnostic radiation represents an indispensable, sometimes life-saving, tool in modern medicine. However, the growing use of computerized tomography (CT) is a topic of concern in radiological protection, especially for children and adolescents. Children are generally more sensitive to the carcinogenic effects of ionizing radiation than adults. In addition, they have a longer life-span to express ...
Voir le projet

 22

 TERMINÉ 

Mapping the life histories of T cells (Life-his-T)

Date du début: 1 mai 2011, Date de fin: 31 janv. 2017,

T cells display many different phenotypes and functions, depending on the nature of previously encountered signals. If we want to understand how these different T cell subsets arise, we need to be able to follow individual T cells and their progeny through time. With the aim to map the life histories of individual T cells we have developed unique technologies that allow us to determine whether dif ...
Voir le projet

 1

 TERMINÉ 

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet

 8

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 

Development of mouse mutant resources for functional analyses of human diseases - Enhancing the translation of research into innovation (INFRAFRONTIER-I3)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

The mouse shows great similarities in development, physiology and biochemistry to humans, which makes it a key model for research into human disease. The major challenges for mouse functional genomics in the 21st century are to:• Develop a series of mutant alleles for every gene in the mouse genome• Determine the phenotypic consequences of each mutation• Identify mouse models for the complete dise ...
Voir le projet

 24

 TERMINÉ 

Tumor Infiltrating Myeloid Cell Compartment (TIMCC)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

"The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally c ...
Voir le projet

 8

 TERMINÉ 

Decoding the ubiquitin code (UBICODE)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,

Ubiquitin (Ub) is a 76 amino acid protein that is commonly found in isopeptide linkage to a lysine residue of a target protein. This post-translational modification controls most cellular processes, including DNA repair, trafficking and protein degradation. Ubiquitin conjugation onto any of its 7 own lysine residues or onto its N-terminus results in a large number of differently linked polymers; t ...
Voir le projet

 2

 TERMINÉ 

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)

Date du début: 1 mai 2013, Date de fin: 31 oct. 2016,

Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Voir le projet

 5

 TERMINÉ 

European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity (EuroTARGET)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical ...
Voir le projet

 15

 TERMINÉ 

Predicting long-term toxic effects using computer models based on systems characterization of organotypic cultures (NOTOX)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"NOTOX will develop and establish a spectrum of systems biological tools including experimental and computational methods for i) organotypic human cell cultures suitable for long term toxicity testing and ii) the identification and analysis of pathways of toxicological relevance. NOTOX will initially use available human HepaRG and primary liver cells as well as mouse small intestine cultures in 3D ...
Voir le projet

 13

 TERMINÉ 

Building data bridges between biological and medical infrastructures in Europe (BIOMEDBRIDGES)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

The ESFRI infrastructures in Biological and BioMedical Sciences face substantial challenges in accessing and sharing data and resources. The BioMedBridges consortium brings together the six established ESFRI infrastructures with common goals to define, implement and deliver data interoperability across the biological and biomedical domains.The first objective is to ensure that interoperable stand ...
Voir le projet

 26

 TERMINÉ 

CAncer Risk and INsulin analoGues (CARING)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

"Several studies have linked the use of insulins to the risk of cancer, and it is certainly plausible that as a growth factor, exposure to administered insulin could stimulate neoplastic growth. However, the meta-analyses of randomized clinical trials comparing different insulin analogues were too small to quantify the risks, especially the proportion of patients that were followed for more than ...
Voir le projet

 8

 TERMINÉ 

European Research Training in the Ubiquitin Proteasome System (UPStream)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The main objective of the international training network UPStream is the training of a novel generation of European scientist in a critical and complex field of modern biology: the understanding of the regulation of the UPS and its potential use for drug development. The importance of this process is illustrated by the imperious necessity to destroy certain proteins during several phases of the ce ...
Voir le projet

 10

 TERMINÉ 

Breast biopsy system guided by Positron Emission Mammography allowing real-time 3D visualization of tumour lesion and needle insertion guidance for higher sampling accuracy and efficiency (MAMMOCARE)

Date du début: 1 sept. 2013, Date de fin: 31 août 2015,

Breast cancer is the most frequent cancer among women and one of the leading causes of cancer-related mortality and early diagnosis is essential to reduce the risk of mortality. First diagnostic tool is clinical imaging (mainly Mammography and Ultrasound) but suspicious findings usually require a biopsy to confirm the diagnosis; 2% of women who undergo a screening mammogram will require some type ...
Voir le projet

 7

 TERMINÉ 

Towards understanding and manipulation of MHC class II antigen presentation (MHC CLASS II-OMICS)

Date du début: 1 sept. 2010, Date de fin: 31 août 2015,

MHC class II molecules are crucial for specific immune responses. In a complicated series of cell biological events, they catch a peptide in the endosomal route for presentation at the plasma membrane to the immune system. At present some 20 factors have been identified as involved in the process of MHC class II antigen presentation that are potential targets for manipulating these responses as MH ...
Voir le projet

 1

 TERMINÉ 

DISSECTING GENETIC DEPENDENCIES IN CANCER (FUNCTIONAL GENOMICS)

Date du début: 1 juin 2010, Date de fin: 31 mai 2015,

While significant progress has been made in the diagnosis and treatment of cancer, several major issues remain unresolved. First, only a minority of patients respond to most forms of (chemo)therapy. It is generally believed that this poor responsiveness to drugs has its origin, at least in part, in the molecular heterogeneity of cancer. This heterogeneity requires the use of biomarkers to stratify ...
Voir le projet

 1

 TERMINÉ 

European Infrastructure of Open Screening Platforms for Chemical Biology (EU-OPENSCREEN)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

The EU-OPENSCREEN Preparatory Phase forms the basis for the construction and operation of a pan-European infrastructure of open screening platforms for Chemical Biology. EU-OPENSCREEN will bring together leading laboratories from 14 European countries covering all aspects of Chemical Biology from high-throughput screening with a dedicated compound library to assay development, chemical synthesis f ...
Voir le projet

 24

 TERMINÉ 

The balance of ubiquitin conjugation and deconjugation (UBIQUITIN BALANCE)

Date du début: 1 févr. 2010, Date de fin: 31 janv. 2015,

Ubiquitin conjugation is one of the most important signaling systems in the eukaryotic cell. Different types of mono- and polyubiquitin chains determine the fate of target proteins by redirecting them for degradation, relocalization or interaction with new partners. The type of ubiquitin modification on any target is determined by the interplay between the conjugating E2/E3 complexes on the one ha ...
Voir le projet

 1

 TERMINÉ 

Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics (PREDICT)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,

"The strategic development of accurate biomarkers to predict response to therapy in cancer medicine will enhance clinical outcome and reduce the health economic impact of drug resistant disease. The PREDICT consortium will identify and validate predictive biomarkers for two drugs which have direct anti-tumour cell and anti-angiogenic activity and for which no established predictive biomarkers of t ...
Voir le projet

 16

 TERMINÉ 

Breast Cancer Somatic Genetics Study (BASIS)

Date du début: 1 juil. 2010, Date de fin: 31 déc. 2014,

"All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million c ...
Voir le projet

 16

 TERMINÉ 

Protecting the food chain from prions: shaping European priorities through basic and applied research (PRIORITY)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2014,

"Bovine Spongiform Encephalopathy (BSE) started, 20 years ago, a devastating health and food crisis throughout Europe. Classical BSE is now under control as a result of the meat and bone meal ban. However, tonsil analyses suggest that there may be an alarmingly high number of asymptomatic PrPSc positive cases. Transmission through blood transfusion is another important concern, as are recent “atyp ...
Voir le projet

 21

 TERMINÉ 

Collaborative Oncological Gene-environment Study (COGS)

Date du début: 1 mai 2009, Date de fin: 31 janv. 2014,

The overarching goal of COGS is to identify individuals with an increased risk of breast, ovary and prostate cancer. Furthermore, we will evaluate the effect of inherited genetic variation on tumour characteristics and clinical outcome. We will do this through quantifying the role of genetic and environmental/lifestyle risk in the largest data set ever generated. In all, we will include over 200,0 ...
Voir le projet

 16

 TERMINÉ 

Identifying novel regulatory mechanisms of miRNA functions (miReg)

Date du début: 1 oct. 2008, Date de fin: 30 sept. 2013,

microRNAs (miRNAs) are master regulators of gene expression capable of defining and altering cell identity. Because of their potency, small size, simple mode of action (target recognition through a Watson-Crick type of base pairing) and the possibility to inhibit them in vivo, miRNAs are valuable therapeutic targets. Recently, we have used novel functional-genetic screening approaches and identifi ...
Voir le projet

 1

 TERMINÉ 

Innate and adaptive immune cell contribution to the pre-metastatic niche (BMDCMET)

Date du début: 1 juin 2011, Date de fin: 31 mai 2013,

"Breast cancer metastasis is a foreboding and prevalent disease for women around the world. Over 90% of breast cancer deaths are caused by metastatic disease emphasizing the urgency for more research in this area. While experimental evidence indicates that tumor cells must acquire specific genetic mutations to disseminate and colonize distant organs, these genetic alterations are not sufficient fo ...
Voir le projet

 1

 TERMINÉ 

Protein stabilization by chemistry: total synthesis of an MHC class I scaffold (PROCHEM)

Date du début: 1 janv. 2011, Date de fin: 22 avr. 2013,

"Technologies for T cell visualisation and T cell depletion/enrichment are steadily making their way into the clinic and developments seem dictated by availability and reliability of the peptide-Major Histocompatibility Complex (pMHC) reagents used. A bottleneck has always been the laborious process of expression, refolding and purification of individual pMHCs. Recently, conditional MHC technology ...
Voir le projet

 1

 TERMINÉ 

barcoding approach for dendritic cells differentiation (BARDIF)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2013,

"Dendritic cells, essential mediators of immunity and tolerance, are not a homogeneous cell type, but display a multitude of different functions and phenotypes. While the heterogeneity in phenotype and function of dendritic cells has been well described, our understanding of the in vivo origin of different dendritic cells subsets is still limited. Identification of the cellular intermediates on th ...
Voir le projet

 1

 TERMINÉ 

Characterization and quantitative modeling of DNA mismatch repair and its role in the maintenance of genomic stability and cancer avoidance (mismatch2model)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2012,

Mismatch2model: Characterization and quantitative modeling of DNA mismatch repair and its role in the maintenance of genomic stability and cancer avoidance DNA mismatch repair (MMR) plays a crucial role in the maintenance of genomic stability. In both bacteria and eukaryotes, the loss of mismatch repair gives rise to a mutator phenotype. In hereditary non-polyposis colon cancer (HNPCC) families, ...
Voir le projet

 6

 TERMINÉ 

European Consortium for Systematic Stem Cell Biology (EUROSYSTEM)

Date du début: 1 mars 2008, Date de fin: 31 août 2012,

EuroSyStem brings together elite European research teams to create a unique and world-leading programme in fundamental stem cell biology. By interconnecting complementary biological and computational expertise we will drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. We will pave the way for application of systems methodology by measuring and modelling ...
Voir le projet

 25